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Haemolytic crisis induced by 
rasburicase administration revealing 
G-6-PD deficiency 
S. Sid, MD1, C. Dugauquier, MD2, B. De Prijck, MD1, C. Bonnet, MD, PhD1, Y. Beguin, MD, PhD1
We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment 
with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydro- 
genase deficiency in some ethnic groups and the importance of a detailed patient and family history 
before starting treatment, even in case of emergency. Glucose-6-phosphate dehydrogenase is an 
essential enzyme since it makes the synthesis of NADPH + H from NADP possible, which determines 
the reducing power (NADPH) of the cell. Every defect in this physiological process, notably glucose-
6-phosphate dehydrogenase deficiency, may thus result simultaneously with the use of rasburicase in 
acute or chronic haemolysis according to the importance of the deficiency. Management is based on 
stopping the incriminated drug and on supportive therapy consisting of administering packed red blood 
cells if the anaemia is poorly tolerated.
(Belg J Hematol 2015;6(2):74-8)
Introduction
Glucose-6-phosphate dehydrogenase (G-6-PD) defi-
ciency is a relatively frequent pathology in some ethnic 
groups and a correctly carried out medical history 
generally makes it possible to avoid prescribing medi-
cation which can cause haemolysis among these patients 
and therefore have detrimental clinical repercussions.
Case report
We report the case of a 27-year-old man of Moroccan 
origin hospitalised for epigastric pain and nausea. 
The patient had no medical antecedent, didn’t smoke 
or drink alcohol and had no other risk factors. He was 
under no medical therapy and had no known allergy.
At the time of his admission, the patient had been 
suffering from epigastralgia and nausea accompanied 
by intermittent pain in his right shoulder for two 
weeks. He reported pale stools and dark urine. His 
close relatives pointed out that he also had presented 
 
a transient jaundice. He was asthenic and anorexic, 
but had not lost weight. He had no fever, but did have 
night sweats. Treatment with omeprazole and domperi-
done had been ineffective.
Clinical examination only identified painful hepatomeg-
aly near the right costal margin. There was no jaundice, 
splenomegaly or lymphadenopathy. Cardio-pulmonary 
and neurological examinations were unremarkable.
The routine admission laboratory tests showed a com-
plete blood count within the normal range (Haemo-
globin: 14g/dL; neutrophils: 4090/µL; lymphocytes: 
2290/µL; platelets: 169000/µL), a mild inflammatory 
syndrome (CRP: 33mg/L; fibrinogen: 4,04g/L), liver 
cholestasis (total bilirubinemia: 13,3mg/L; alkaline 
phosphatases: 318UI/L; γGT: 344UI/L) and cytolysis 
(SGOT: 83UI/L; SGPT: 176UI/L; LDH: 990UI/L). 
There was no cardiac (creatine phosphokinase: 66UI/L; 
CK-MB: 2,2µg/L; CK-MB/creatine kinase: 3,4µg/100UI; 
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troponin T < 0,01µg/L), kidney (urea: 0,32g/L; creati-
nine: 7mg/L; GFR: >60mL/min) or pancreatic (lipase: 
26UI/L) impairment. There was no sign of denutrition 
(total proteins: 71g/L; albumin: 39g/L). Uric acid was 
slightly elevated (73mg/L).
Abdominal ultrasonography demonstrated multiple 
hepatic lesions suggestive of abscesses and associated 
with splenomegaly (12,5cm).
An abdominal CT scan (Figure 1) invalidated the pres-
ence of hepatic abscess and suggested a differential 
diagnosis between nodular steatosis, lymphoma, chol-
angiocarcinoma and hepatic lesions due to a systemic 
disease. 
Infectious serologies ruled out HAV, HBV, HCV, HIV, 
brucella, bartonella, coxiella or taenia infections.
A liver biopsy provided the final diagnosis of Burkitt’s 
lymphoma. The patient received hyperhydratation and 
allopurinol prophylaxis.
The patient was then transferred to our haematology 
department for further testing. Bone marrow biopsy 
revealed massive infiltration by the lymphoma and the 
PET-scan showed disseminated hepatic lesions associ-
ated with peritoneal involvement, a right renal lesion 
and an intensely hypermetabolic bone marrow. Neuro-
meningeal assessment disclosed no CNS involvement.
The patient was placed on corticotherapy. Allopurinol 
was replaced by rasburicase. Two days later, routine 
evaluation of oxygen disclosed venous oxygen saturation 
at 60%. Oxygen saturation in arterial blood was 80% 
and there was 15% methemoglobin. The haemoglobin 
dropped from 11.6g/dL the night before to 9,1g/dL in 
the morning and 6,5g/dL in the afternoon (Figure 2). 
The patient then developed intense hemoglobinuria 
associated with drowsiness and deep asthenia. More 
exhaustive family history revealed that two of his 
brothers suffered from G-6-PD deficiency and that the 
patient himself presented an episode of hematuria at 
the age of eighteen after ingesting beans. The diagnosis 
of G-6-PD deficiency was confirmed and the patient 
was transferred to the intensive care unit for two days 
where he evolved favourably after transfusion of packed 
cells without any use of vasoactive drugs. He started 
his chemotherapy after returning to our department 
and went into complete remission.
Discussion
Pathophysiology
G-6-PD is an enzyme that catalyses the transformation 
of glucose-6-phosphate (G-6-P) into 6-phosphogluco-
no-δ-lactone within the pentose phosphate pathway 
(Figure 3).1 This step is essential as it also makes the 
synthesis of NADPH + H+ from NADP+ possible, deter-
mining the reducing power (NADPH) of the cell.
NADPH enables erythrocytes to reduce the oxidised 
glutathione, glutathione-disulfide (GSSG) produced from 
reduced glutathione and H2O2, the latter coming from 
the release of O2 superoxide. As the function of gluta-
thione is to prevent damage to important cellular com-
ponents caused by reactive oxygen species, G-6-PD plays 
an essential role in the regeneration of the reducing 
power of erythrocytes, preventing the attack on mem-
brane lipids by oxidising agents and in fine impeding 
cell lysis. Every defect in this physiological process, 
especially G-6-PD deficiency, will result in acute or 
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Figure 1. Abdominal CT scan of the patient at presentation 
showing multiple hepatic lesions.
Table 1. List of drugs to avoid in G-6-PD deficiency.
Dapsone 





Tolonium chloride (toluidine blue) 
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chronic haemolysis according to the importance of the 
deficiency.
In our particular case, the administration of rasburicase, 
which is an oxidant agent, will cause a depletion of 
glutathione in the red blood cells and the oxidation 
of sulfhydryl-containing proteins of the membrane of 
the cell. The erythrocytes will become rigid and non 
deformable and then be destroyed by the reticuloendo-
thelial macrophages.
The G-6-PD gene is localised on the long arm of chromo-
some X.2 G-6-PD deficiency is consequently inherited 
as an X linked disease. All of the red cells in affected 
males are susceptible to haemolysis. The homozygous 
females are as severely affected as hemizygous males 
but concerning the heterozygous females, the severity 
will depend on the degree of X chromosome inactivation 
(lyonization) and the degree to which the abnormal 
G-6-PD variant is expressed. Each red blood cell ex-
presses only one chromosome X. If it is the abnormal 
one, the cell will be susceptible to haemolysis.
The World Health Organisation classified the different 
forms of G-6-PD deficiency into five categories, accord-
ing to enzyme activity.3 The first category is the most 
serious form of G-6-PD deficiency and has chronic 
haemolytic anaemia. The second and third categories 
are characterised by intermittent episodes of acute 
haemolysis induced by infections, drugs and various 
other substances. The fourth category corresponds to 
normal enzyme activity, whereas the fifth category 
includes enzymes with supraphysiological activity.
Epidemiology
The number of people affected by G-6-PD deficiency is 
estimated at 400 million world wide, with the highest 
prevalence in Sub-Saharan Africa.4 It is to be noted that 
some ethnic groups are more affected than others, par-
ticularly the Jewish Kurds among whom the prevalence 
can reach 60-70% in men.5
Clinical aspects
Most patients carrying G-6-PD deficiency are asymp-
tomatic and the disease only manifests after eating 
beans, during an infection or after the administration of 
specific drugs, increasing oxidative stress in red blood 
cells. In these conditions, the oldest red blood cells 
undergo haemolysis because they contain less G-6-PD. 
This haemolysis classically appears between two to four 
days after administering the pro-oxidant agent with 
anaemia, jaundice, variable hemoglobinuria, asthenia 
and back pain.6




























Management is based on stopping the incriminated drug 
and on supportive therapy consisting of administering 
packed red blood cells if the anaemia is poorly tolerated.
Prophylaxis is based on avoidance of drugs that may 
cause haemolysis in these patients. Some confusion 
exists as to the precise list of incriminated medicines 
and a recent literature review concluded that many 
medications had wrongly been accused following hae-
molysis developing in the context of an infection where 
patients received these drugs.7 Authors concluded that 
only seven medicines in the pharmacopoeia have actu-
ally been proven noxious (Table 1).
The use of folic acid at 1mg/day can be beneficial to 
support erythropoiesis in patients affected by the more 
serious forms of the deficiency.
Modest results have been obtained in anecdotal cases 
after splenectomy or after administration of vitamin E.8-10 
 
Consequently, these treatments are generally not recom-
mended.11 Some improvement of the deficiency has 
been achieved by gene transfer using a viral vector in 
mouse stem cells.12 However, this experimentation is 
still at the pre-clinical stage.
The acute haemolysis we report here was induced by 
rasburicase, a recombinant version of urate oxidase that 
catalyses the transformation of uric acid into allantoin. 
This medication has been used in the prophylaxis of 
hyperuricemia in haematological malignancies since 
2001.13 Though other cases have already been reported 
in the literature, this is a rare complication of this treat-
ment.14-21
Conclusion
This case reminds us of the fact that G-6-PD deficiency 
is a relatively frequent pathology in some ethnic groups 
Figure 3. Regeneration of the reduced power of erythrocytes within the pentose phosphate pathway.
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and that a correctly carried out medical history gener-
ally makes it possible to avoid prescribing medications 
that can cause serious haemolysis.
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Key messages for clinical practice
1. Glucose-6-phosphate dehydrogenase is an essential enzyme as it synthesises NADPH + H from 
NADP, which determines the reducing power (NADPH) of the cell. Every defect in this physiological 
process, notably glucose-6-phosphate dehydrogenase deficiency, will thus result in acute or 
chronic haemolysis according to the importance of the deficiency.
2. This defect is linked to chromosome X: a family history is an important aspect of the diagnosis.
3. Management is based on stopping the incriminated drug and on supportive therapy consisting 
of administering packed red blood cells if the anaemia is poorly tolerated.
4. List of drugs to avoid in glucose-6-phosphate dehydrogenase deficiency: dapsone, methylthion-
inium chloride (methylene blue), nitrofurantoine, phenazopyridine, primaquine, rasburicase, tolonium 
chloride (toluidine blue).
